|Over a week ago|
CEL-SCI offering increased to 630,500 shares at price of $12.22 » 13:1803/2503/25/20
CEL-SCI announced yesterday morning that due to demand, the underwriter has agreed to increase the size of its previously announced offering and purchase on a firm commitment basis 630,500 shares of common stock of the company, at a price to the public of $12.22 per share, representing a 5% discount to the closing price per share. The closing of the offering is expected to occur on or about March 26. Aegis Capital is acting as the sole book-running manager for the offering. The gross proceeds to CEL-SCI before deducting underwriting discounts and commissions and estimated offering expenses and assuming no exercise of the option to purchase additional shares of common stock, are expected to be approximately $7.7M. CEL-SCI intends to use the net of the offering to fund the continued development of Multikine, LEAPS and for other general corporate purposes.
Fly Intel: Pre-market Movers » 09:0903/2403/24/20
GNW, SPCE, NVAX, CTMX, BA, INFO, QIWI, CMCM, CVM, MIST, IVR, BXRX
Check out this morning's…
CEL-SCI announces bought deal offering » 07:4403/2403/24/20
CEL-SCI announced today…
CEL-SCI announced today that it has entered into an underwriting agreement with Aegis Capital Corp. under which the underwriter has agreed to purchase on a firm commitment basis a minimum of 500,000 shares of common stock of the Company, at a price to the public of $12.22 per share Aegis Capital Corp. is acting as the sole book-running manager for the offering.
CEL-SCI initiates development of immunotherapy to treat COVID-19 » 08:1203/0903/09/20
CEL-SCI announces that it…
CEL-SCI announces that it is developing an immunotherapy with the potential to treat the COVID-19 coronavirus using its patented LEAPS peptide technology. The LEAPS peptides will utilize conserved regions of coronavirus proteins to stimulate protective cell mediated T cell responses and reduce viral load. The LEAPS peptide technology can be used to construct immunotherapeutic peptides that exhibit both antiviral and anti-inflammatory properties. Consequently, these products not only target the virus infection against which they are directed, but also elicit the appropriate protective response(s) against it. Predictions of success using the LEAPS peptides against COVID-19 coronavirus are based on previous studies conducted in collaboration with the National Institutes for Allergies and Infectious Diseases, or NIAID, with another respiratory virus, pandemic influenza, or H1N1. In those studies, LEAPS peptides elicited protection of mice from morbidity and mortality after the introduction of infection by activating appropriate T cell responses rather than an inflammatory response. Although individuals of all ages are susceptible to COVID-19 coronavirus infection, the elderly and individuals with compromised lung function or immunosuppression are at highest risk for severe morbidity and mortality. It is believed that, in most cases, onset of symptoms takes between 2 and 14 days post infection, a period of time that may allow intervention for those at highest risk and with a known exposure.
|Over a month ago|
CEL-SCI off lows after CEO letter to shareholders » 15:2902/2602/26/20
Shares of CEL-SCI, which…
Shares of CEL-SCI, which dropped to as low as $7.20 earlier this afternoon, have rebounded somewhat and are now trading at $9.42 following a letter to shareholders from CEL-SCI CEO Geert Kersten which said that Multikine, which has been in Phase 3 trial since 2011, is likely producing "some kind of a survival benefit." Despite the uptick, shares of CEL-SCI are still down over 42% on the day, having opened at $15.76.
CEL-SCI CEO says Multikine likely producing 'some kind of a survival benefit' » 15:2502/2602/26/20
CEL-SCI CEO Geert Kersten…
CEL-SCI CEO Geert Kersten issued a letter to shareholders, stating: "The Phase 3 trial of our investigational cancer immunotherapy, Multikine is designed to demonstrate that we can be even more successful in increasing the overall survival (OS) of cancer patients when we stimulate their immune systems before they are ravaged by the effects of surgery, radiation, and/or chemotherapy. The global pivotal Phase 3 clinical trial, which we started nine years ago for our Multikine immunotherapy in advanced primary head and neck cancer patients, tests the hypothesis that giving the Multikine treatment regimen right after cancer diagnosis, BEFORE surgery, radiation or radiochemotherapy, will increase the OS of patients beyond the OS achieved with the current "intent to cure" standard of care therapies. In short, we seek to make the current "intent to cure" SOC treatment more successful. And we hope to do so with little to no toxicity added by our Multikine immunotherapy... We are blinded to the Phase 3 study results. However, it is clear that there is something occurring in our study that is keeping patients alive longer than expected. By eliminating the factors other than Multikine that could contribute to this observed delay in reaching the required events, and because it is now established that cancer immunotherapy can produce a delayed survival benefit, we believe that Multikine is likely producing some kind of a survival benefit, just as it did in the final Phase 2 study. We are treating advanced (stages 3 and 4) primary (just diagnosed and not yet treated) head and neck cancer patients who have cancer in the worst anatomical regions with regard to survival outcome. They simply do not get better on their own. In its annual reports published in January 2019 and January 2020 the American Cancer Society indicated that deaths in oral cancer patients have increased during the past 10 years. This report confirms that the current SOC treatment or treatments that patients are receiving if their tumor recurs have not improved in the nine years since we started our Phase 3 study and validates that an extreme unmet medical need still exists for these patients. We believe that we are nearing the end of this long Phase 3 study, and we hope the results will prove that stimulating the immune systems of cancer patients with Multikine to fight cancer BEFORE they are ravaged by the effects of surgery, radiation, and chemotherapy will help these patients to survive longer. And if we can do so with little to no toxicity as we did in our earlier Multikine studies, then we will have made a huge contribution to the cancer armamentarium."
Cel Sci trading resumes 14:5202/2602/26/20
Cel Sci trading halted, volatility trading pause 14:4202/2602/26/20
Cel Sci put volume heavy and directionally bearish » 12:3502/2602/26/20
Bearish flow noted in Cel…
Bearish flow noted in Cel Sci with 3,026 puts trading, or 1.4x expected. Most active are Jun-20 7.5 puts and Mar-20 7.5 puts, with total volume in those strikes near 1,300 contracts. The Put/Call Ratio is 2.37, while ATM IV is up nearly 10 points on the day. Earnings are expected on May 11th.
CEL-SCI management to meet with SunTrust » 04:5502/2602/26/20
Meeting to be held in…
Meeting to be held in Texas on February 26 hosted by SunTrust.